Please assess the completion status of the following clinical trial:

Trial Title: VA Augmentation and Switching Treatments for Improving Depression Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of single or recurrent, non-psychotic, major depressive disorder~* Currently taking a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) or mirtazapine for major depressive disorder~* Need for next-step treatment based on documented suboptimal outcome from current antidepressant treatment for major depressive episode (at least 6 weeks treatment with a QIDS-C16 \>= 16 or at least 8 weeks with a QIDS-C16 \>= 11; and at least 3 weeks at a stable optimal dose~* Age: 18 years of age or older~Exclusion Criteria:~* Prior inadequate response after an adequate treatment trial or clear cut intolerance to either of the study medications (aripiprazole or bupropion)~* Current treatment with bupropion, aripiprazole or any other antipsychotic agent~* Lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder, or psychosis not otherwise specified~* Current diagnosis of Dementia~* Current diagnosis of an eating disorder or a seizure disorder~* High suicide risk currently requiring acute intervention (other than outpatient treatment of depression)~* Unstable, serious medical condition or one requiring acute medical treatment, or anticipation of hospitalization for extended care~* Requiring immediate hospitalization for psychiatric disorders~* Physiologic substance dependence requiring detoxification (excluding nicotine) in the past 30 days (substance abuse is not an exclusion criteria)~* Taking any concomitant medication that contraindicates any of treatment options or augmenting agents known to have an antidepressant effect~* Concurrent or recent participation (within the last 30 days) in another conflicting clinical trial with a mental health, investigational drug, or medical device intervention~* Female - pregnant or lactating or planning to become pregnant~* Patient was not able or willing to provide informed consent; or changed mind about participating prior to randomization~* Patient was not referred to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Switching: Bupropion-SR (Type: ACTIVE_COMPARATOR): Switching: Bupropion-SR
- Augmenting: Antidepressant + Bupropion-SR (Type: ACTIVE_COMPARATOR): Augmenting: Antidepressant + Bupropion-SR
- Augmenting: Antidepressant + Aripiprazole (Type: ACTIVE_COMPARATOR): Augmenting: Antidepressant + Aripiprazole

Based on this trial design, predict the completion outcome and termination type (if applicable).